Compare COMBAT DRUGS with - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

COMBAT DRUGS vs LASA SUPERGENERICS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    COMBAT DRUGS LASA SUPERGENERICS COMBAT DRUGS/
LASA SUPERGENERICS
 
P/E (TTM) x 24.5 -91.8 - View Chart
P/BV x 3.7 1.5 247.4% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 COMBAT DRUGS   LASA SUPERGENERICS
EQUITY SHARE DATA
    COMBAT DRUGS
Mar-20
LASA SUPERGENERICS
Mar-21
COMBAT DRUGS/
LASA SUPERGENERICS
5-Yr Chart
Click to enlarge
High Rs34100 34.1%   
Low Rs1627 60.0%   
Sales per share (Unadj.) Rs23.749.8 47.7%  
Earnings per share (Unadj.) Rs1.15.6 19.5%  
Cash flow per share (Unadj.) Rs1.69.5 17.3%  
Dividends per share (Unadj.) Rs00.25 0.0%  
Avg Dividend yield %00.4 0.0%  
Book value per share (Unadj.) Rs12.439.1 31.8%  
Shares outstanding (eoy) m10.1040.67 24.8%   
Bonus / Rights / Conversions ---  
Price / Sales ratio x1.11.3 83.0%   
Avg P/E ratio x23.111.4 203.4%  
P/CF ratio (eoy) x15.36.7 229.1%  
Price / Book Value ratio x2.01.6 124.4%  
Dividend payout %04.5 0.0%   
Avg Mkt Cap Rs m2542,586 9.8%   
No. of employees `000NANA-   
Total wages/salary Rs m196140 139.5%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m2402,024 11.9%  
Other income Rs m32 156.0%   
Total revenues Rs m2432,026 12.0%   
Gross profit Rs m25472 5.3%  
Depreciation Rs m6158 3.5%   
Interest Rs m821 37.4%   
Profit before tax Rs m15295 5.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m467 5.4%   
Profit after tax Rs m11228 4.8%  
Gross profit margin %10.523.3 45.1%  
Effective tax rate %24.922.8 109.4%   
Net profit margin %4.611.3 40.8%  
BALANCE SHEET DATA
Current assets Rs m244643 37.9%   
Current liabilities Rs m230405 56.8%   
Net working cap to sales %5.611.8 47.3%  
Current ratio x1.11.6 66.7%  
Inventory Days Days1171 11,066.7%  
Debtors Days Days222266 83.5%  
Net fixed assets Rs m1271,435 8.8%   
Share capital Rs m101407 24.8%   
"Free" reserves Rs m251,182 2.1%   
Net worth Rs m1261,589 7.9%   
Long term debt Rs m00-   
Total assets Rs m3702,079 17.8%  
Interest coverage x2.915.3 19.0%   
Debt to equity ratio x00-  
Sales to assets ratio x0.61.0 66.6%   
Return on assets %5.112.0 42.4%  
Return on equity %8.814.3 61.1%  
Return on capital %17.819.9 89.8%  
Exports to sales %017.0 0.0%   
Imports to sales %00.9 0.0%   
Exports (fob) Rs mNA345 0.0%   
Imports (cif) Rs mNA19 0.0%   
Fx inflow Rs m0345 0.0%   
Fx outflow Rs m019 0.0%   
Net fx Rs m0326 0.0%   
CASH FLOW
From Operations Rs m-152413 -36.7%  
From Investments Rs m-1-36 3.4%  
From Financial Activity Rs m180-364 -49.5%  
Net Cashflow Rs m2813 223.9%  

Share Holding

Indian Promoters % 0.0 64.5 -  
Foreign collaborators % 45.9 0.0 -  
Indian inst/Mut Fund % 0.0 0.0 -  
FIIs % 0.0 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 54.1 35.5 152.2%  
Shareholders   12,796 23,066 55.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare COMBAT DRUGS With:   TTK HEALTHCARE  SANJIVANI PA  MOREPEN LABS  ZOTA HEALTH CARE  SAMRAT PHARMA  



Today's Market

Bloodbath on Dalal Street: 6 Reasons Why Sensex Slumped 1,688 Points Today(Closing)

Indian share markets witnessed negative trading activity throughout the day today and ended deep in the red.

Related Views on News

LASA SUPERGENERICS 2020-21 Annual Report Analysis (Annual Result Update)

Nov 9, 2021 | Updated on Nov 9, 2021

Here's an analysis of the annual report of LASA SUPERGENERICS for 2020-21. It includes a full income statement, balance sheet and cash flow analysis of LASA SUPERGENERICS. Also includes updates on the valuation of LASA SUPERGENERICS.

More Views on News

Most Popular

Infosys vs TCS: Which is Better?(Views On News)

Nov 26, 2021

In the post pandemic era, the top two IT companies in India are fighting to capture the growing demand for IT.

This Multibagger Stock Zooms 20% After Dolly Khanna Buys Stake(Views On News)

Nov 24, 2021

Shares of this edible oil company zoomed over 50% in three days after ace investor bought around 1% stake.

How to Hit Rs 100 Crore Wealth in Your Lifetime(Equitymaster Wealth)

Nov 15, 2021

This is how you can achieve the ambitious goal of a net worth of Rs 100 crore.

Don't Sell these Stocks if the Market Falls(Profit Hunter)

Nov 17, 2021

These are the 3 types of stocks that you should not sell in a market crash.

MobiKwik IPO Opens for Subscription Soon. Key Things to Know Before Subscribing.(Views On News)

Nov 20, 2021

The Rs 19 bn issue is set to hit the market soon.

More

Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

COMBAT DRUGS SHARE PRICE


Nov 26, 2021 (Close)

TRACK COMBAT DRUGS

  • Track your investment in COMBAT DRUGS with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

COMBAT DRUGS 5-YR ANALYSIS

COMPARE COMBAT DRUGS WITH

MARKET STATS